HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

USE OF THIOCTIC ACID IN PATIENTS WITH DIABETES MELLITUS TYPE 2

Download full text PDF
Issue: 
12
Year: 
2015

Professor M. Zhuravleva, MD; Professor V. Kukes, Academician of the Russian Academy of Sciences; G. Gorodetskaya; Professor A. Prokofyev, MD; S. Serebrova; T. Chernykh; Professor E. Shikh, MD; V. Arkhipov I.M. Sechenov First Moscow State Medical Universit

Thioctic acid (TA) that is not a drug to treat diabetes mellitus has direct indications for its complications, diabetic polyneuropathy (DPN) in particular. Today TA is recognized as the only pathogenetic agent for the treatment of DPN and included in both international guidelines and the Russian medical care standards developed by the Ministry of Health of Russia.

Keywords: 
diabetes mellitus
diabetic polyneuropathy
thioctic acid



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. WHO. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus // Diabetes Care. – 1999; 23 (Suppl. 1): 4–19.
  2. Algoritmy spetsializirovannoj meditsinskoj pomoschi bol'nym sahar nym diabetom. 7-j vyp. // Saharnyj diabet. – 2015; 18 (Pril.): 112.
  3. Balabolkin M.I. Diabetologija / M.: Meditsina, 2000; 672 s.3.
  4. Watkins P., Thomas P. Diabetes mellitus and the nervous system // J. 4. Neurol. Neurosurg. Psychiatr. – 1998; 65: 620–33.
  5. Davies M., Brophy S., Williams R. et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes // Diabetes Care. – 2006; 29 (7): 1518–22.
  6. Vallianou N., Evangelopoulos A., Koutalas P. Alpha-lipoic acid and diabetic neuropathy // Rev. Diabet. Stud. – 2009; 6 (4): 230–6.
  7. Balabolkin M.I., Chernyshova T.E., Trusov V.V. i dr. Diabeticheskaja nejropatija: patogenez, diagnostika, klassifikatsija, prognosticheskoe znache-nie, lechenie (uchebno-metodicheskoe posobie) / M.: Ekspertiza, 2003; s. 3–105.
  8. Hutornaja O.E., Bregovskij V.B., Demina A.G. i dr. Geterogennost' bole voj diabeticheskoj polinejropatii i differentsirovannyj podhod k ee lecheniju // Saharnyj diabet. – 2013; 2: 62–6.
  9. Berri D., Kukes V.G., Sokolov A.V. i dr. Terapevticheskij lekarstvennyj monitoring // Lekarstvennye preparaty i ratsional'naja farmakoterapija. – 2013; 1: 5–21.
  10. Packer L., Witt E., Tritschler H. Alpha-Lipoic acid as a biological antioxidant // Free Radic. Biol. Med. – 1995; 19 (2): 227–50.
  11. Zanozina O.V., Sorokina Ju.A., Borovkov N.N. i dr. «Porochnyj krug» vzaimosvjazi perekisnogo okislenija lipidov i okislitel'noj modifikatsii belkov u bol'nyh saharnym diabetom tipa 2 // Med. al'manah. – 2013; 6: 167–70.
  12. Belousov Ju.B., Gurevich K.G. Klinicheskaja farmakokinetika. Praktika dozirovanija lekarstv: Spets. vyp. serii «Ratsional'naja farmakoterapija» / M.: Litterra, 2005; 288 s.
  13. Rowland M., Tozer R. Clinical. Pharmacokinetics. Concepts and applications / Baltimore, Philadelphia, Hong Kong and so on, 1995; 5.
  14. Eichler H., Muller M. Drug distribution. The forgotten relative in clinical . pharmacokinetics // Clin. Pharmacokinet. – 1998; 34 (2): 95–9.
  15. Ziegler D., Hanefeld M., Ruhnau K. et al. Treatment of symptomatic peripheral neuropathy with the anti-oxidant α-lipoic acid // Diabetologia. – 1995; 38: 1425–33.
  16. Hermann R., Niebch G., Borbe H. et al. Enantioselective pharmacokinetics 16. and bioavailability of different racemic alpha-lipoic acid formulations in healthy volunteers // Eur. J. Pharm. Sci. – 1996; 4: 167–74.
  17. Setkina S.B., Hishova O.M. Biofarmatsevticheskie aspekty tehnolo-17. gii lekarstvennyh sredstv i puti modifikatsii biodostupnosti // Vestnik VGMU. – 2014; 13 (4): 162–72.
  18. Poh Z., Goh K. A current update on the use of alpha lipoic acid in the 18. management of type 2 diabetes mellitus // Endocr. Metabol. Immun. Disord. Drug Targets. – 2009; 9 (4): 392–8.
  19. Ametov A., Barinov A., O’Brien P. et al. The sensory symptoms of diabetic 19. polyneuropathy are improved with α-lipoic acid: the SYDNEY trial // Diabetes Care. – 2003; 26: 770–6.